Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs.
Jaeki MinAnand MayasundariFatemeh KeramatniaBarbara JonchereSeung Wook YangJamie JarusiewiczMarisa ActisSourav DasBrandon YoungJake SlavishLei YangYong LiXiang FuShalandus H GarrettMi-Kyung YunZhenmei LiStanley NithiananthamSergio ChaiTaosheng ChenAnang ShelatRichard E LeeGisele NishiguchiStephen W WhiteMartine F RousselPatrick Ryan PottsMarcus FischerZoran RankovicPublished in: Angewandte Chemie (International ed. in English) (2021)
Targeting cereblon (CRBN) is currently one of the most frequently reported proteolysis-targeting chimera (PROTAC) approaches, owing to favorable drug-like properties of CRBN ligands, immunomodulatory imide drugs (IMiDs). However, IMiDs are known to be inherently unstable, readily undergoing hydrolysis in body fluids. Here we show that IMiDs and IMiD-based PROTACs rapidly hydrolyze in commonly utilized cell media, which significantly affects their cell efficacy. We designed novel CRBN binders, phenyl glutarimide (PG) analogues, and showed that they retained affinity for CRBN with high ligand efficiency (LE >0.48) and displayed improved chemical stability. Our efforts led to the discovery of PG PROTAC 4 c (SJ995973), a uniquely potent degrader of bromodomain and extra-terminal (BET) proteins that inhibited the viability of human acute myeloid leukemia MV4-11 cells at low picomolar concentrations (IC50 =3 pM; BRD4 DC50 =0.87 nM). These findings strongly support the utility of PG derivatives in the design of CRBN-directed PROTACs.
Keyphrases
- acute myeloid leukemia
- single cell
- cell therapy
- endothelial cells
- induced apoptosis
- ionic liquid
- emergency department
- photodynamic therapy
- small molecule
- stem cells
- immune response
- high throughput
- signaling pathway
- drug delivery
- heavy metals
- bone marrow
- rheumatoid arthritis
- disease activity
- allogeneic hematopoietic stem cell transplantation
- acute lymphoblastic leukemia
- adverse drug
- pluripotent stem cells